Literature DB >> 27521655

Two is better than one; toward a rational design of combinatorial therapy.

Sheng-Hong Chen1, Galit Lahav2.   

Abstract

Drug combination is an appealing strategy for combating the heterogeneity of tumors and evolution of drug resistance. However, the rationale underlying combinatorial therapy is often not well established due to lack of understandings of the specific pathways responding to the drugs, and their temporal dynamics following each treatment. Here we present several emerging trends in harnessing properties of biological systems for the optimal design of drug combinations, including the type of drugs, specific concentration, sequence of addition and the temporal schedule of treatments. We highlight recent studies showing different approaches for efficient design of drug combinations including single-cell signaling dynamics, adaption and pathway crosstalk. Finally, we discuss novel and feasible approaches that can facilitate the optimal design of combinatorial therapy.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27521655      PMCID: PMC5469547          DOI: 10.1016/j.sbi.2016.07.020

Source DB:  PubMed          Journal:  Curr Opin Struct Biol        ISSN: 0959-440X            Impact factor:   6.809


  42 in total

1.  PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer.

Authors:  Ana Bosch; Zhiqiang Li; Anna Bergamaschi; Haley Ellis; Eneda Toska; Aleix Prat; Jessica J Tao; Daniel E Spratt; Nerissa T Viola-Villegas; Pau Castel; Gerard Minuesa; Natasha Morse; Jordi Rodón; Yasir Ibrahim; Javier Cortes; Jose Perez-Garcia; Patricia Galvan; Judit Grueso; Marta Guzman; John A Katzenellenbogen; Michael Kharas; Jason S Lewis; Maura Dickler; Violeta Serra; Neal Rosen; Sarat Chandarlapaty; Maurizio Scaltriti; José Baselga
Journal:  Sci Transl Med       Date:  2015-04-15       Impact factor: 17.956

Review 2.  Tumor adaptation and resistance to RAF inhibitors.

Authors:  Piro Lito; Neal Rosen; David B Solit
Journal:  Nat Med       Date:  2013-11       Impact factor: 53.440

3.  Recurrent initiation: a mechanism for triggering p53 pulses in response to DNA damage.

Authors:  Eric Batchelor; Caroline S Mock; Irun Bhan; Alexander Loewer; Galit Lahav
Journal:  Mol Cell       Date:  2008-05-09       Impact factor: 17.970

4.  The dynamics of signaling as a pharmacological target.

Authors:  Marcelo Behar; Derren Barken; Shannon L Werner; Alexander Hoffmann
Journal:  Cell       Date:  2013-10-10       Impact factor: 41.582

5.  Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.

Authors:  Siwen Hu-Lieskovan; Stephen Mok; Blanca Homet Moreno; Jennifer Tsoi; Lidia Robert; Lucas Goedert; Elaine M Pinheiro; Richard C Koya; Thomas G Graeber; Begoña Comin-Anduix; Antoni Ribas
Journal:  Sci Transl Med       Date:  2015-03-18       Impact factor: 17.956

Review 6.  Crosstalk between hedgehog and other signaling pathways as a basis for combination therapies in cancer.

Authors:  Jillian Brechbiel; Karen Miller-Moslin; Alex A Adjei
Journal:  Cancer Treat Rev       Date:  2014-02-24       Impact factor: 12.111

7.  Stimulus specificity of gene expression programs determined by temporal control of IKK activity.

Authors:  Shannon L Werner; Derren Barken; Alexander Hoffmann
Journal:  Science       Date:  2005-09-16       Impact factor: 47.728

8.  Growth factor-induced MAPK network topology shapes Erk response determining PC-12 cell fate.

Authors:  Silvia D M Santos; Peter J Verveer; Philippe I H Bastiaens
Journal:  Nat Cell Biol       Date:  2007-02-18       Impact factor: 28.824

9.  Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks.

Authors:  Michael J Lee; Albert S Ye; Alexandra K Gardino; Anne Margriet Heijink; Peter K Sorger; Gavin MacBeath; Michael B Yaffe
Journal:  Cell       Date:  2012-05-11       Impact factor: 41.582

10.  MDM4 is a key therapeutic target in cutaneous melanoma.

Authors:  Agnieszka Gembarska; Flavie Luciani; Clare Fedele; Elisabeth A Russell; Michael Dewaele; Stéphanie Villar; Aleksandra Zwolinska; Sue Haupt; Job de Lange; Dana Yip; James Goydos; Jody J Haigh; Ygal Haupt; Lionel Larue; Aart Jochemsen; Hubing Shi; Gatien Moriceau; Roger S Lo; Ghanem Ghanem; Mark Shackleton; Federico Bernal; Jean-Christophe Marine
Journal:  Nat Med       Date:  2012-07-22       Impact factor: 53.440

View more
  21 in total

1.  Mechanistic Distinctions between CHK1 and WEE1 Inhibition Guide the Scheduling of Triple Therapy with Gemcitabine.

Authors:  Siang-Boon Koh; Yann Wallez; Charles R Dunlop; Sandra Bernaldo de Quirós Fernández; Tashinga E Bapiro; Frances M Richards; Duncan I Jodrell
Journal:  Cancer Res       Date:  2018-05-07       Impact factor: 12.701

2.  p53 dynamics in response to DNA damage vary across cell lines and are shaped by efficiency of DNA repair and activity of the kinase ATM.

Authors:  Jacob Stewart-Ornstein; Galit Lahav
Journal:  Sci Signal       Date:  2017-04-25       Impact factor: 8.192

3.  The National Cancer Institute ALMANAC: A Comprehensive Screening Resource for the Detection of Anticancer Drug Pairs with Enhanced Therapeutic Activity.

Authors:  Susan L Holbeck; Richard Camalier; James A Crowell; Jeevan Prasaad Govindharajulu; Melinda Hollingshead; Lawrence W Anderson; Eric Polley; Larry Rubinstein; Apurva Srivastava; Deborah Wilsker; Jerry M Collins; James H Doroshow
Journal:  Cancer Res       Date:  2017-04-26       Impact factor: 12.701

4.  Feedback analysis identifies a combination target for overcoming adaptive resistance to targeted cancer therapy.

Authors:  Sang-Min Park; Chae Young Hwang; Jihye Choi; Chang Young Joung; Kwang-Hyun Cho
Journal:  Oncogene       Date:  2020-03-10       Impact factor: 9.867

5.  p52-ZER6: a determinant of tumor cell sensitivity to MDM2-p53 binding inhibitors.

Authors:  Wen-Fang Li; Leader Alfason; Can Huang; Yu Tang; Li Qiu; Makoto Miyagishi; Shou-Rong Wu; Vivi Kasim
Journal:  Acta Pharmacol Sin       Date:  2022-08-22       Impact factor: 7.169

6.  A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.

Authors:  Juana Fernández-Rodríguez; Edgar Creus-Bachiller; Xiaohu Zhang; Maria Martínez-Iniesta; Sara Ortega-Bertran; Rajarshi Guha; Craig J Thomas; Margaret R Wallace; Cleofe Romagosa; Lourdes Salazar-Huayna; Karlyne M Reilly; Jaishri O Blakely; Jordi Serra-Musach; Miguel Angel Pujana; Eduard Serra; Alberto Villanueva; Marc Ferrer; Conxi Lázaro
Journal:  Mol Cancer Ther       Date:  2022-07-05       Impact factor: 6.009

7.  Differential regulation of autophagy by STAU1 in alveolar rhabdomyosarcoma and non-transformed skeletal muscle cells.

Authors:  Shekoufeh Almasi; Tara E Crawford Parks; Aymeric Ravel-Chapuis; Alex MacKenzie; Jocelyn Côté; Kyle N Cowan; Bernard J Jasmin
Journal:  Cell Oncol (Dordr)       Date:  2021-04-26       Impact factor: 6.730

8.  Looking beyond the cancer cell for effective drug combinations.

Authors:  Jonathan R Dry; Mi Yang; Julio Saez-Rodriguez
Journal:  Genome Med       Date:  2016-11-25       Impact factor: 11.117

9.  Inorganic Nanomaterial-Mediated Gene Therapy in Combination with Other Antitumor Treatment Modalities.

Authors:  Guanyou Lin; Richard A Revia; Miqin Zhang
Journal:  Adv Funct Mater       Date:  2020-10-13       Impact factor: 18.808

10.  Intracellular Delivery of Doxorubicin by Iron Oxide-Based Nano-Constructs Increases Clonogenic Inactivation of Ionizing Radiation in HeLa Cells.

Authors:  Roxana Cristina Popescu; Diana Iulia Savu; Miriam Bierbaum; Adriana Grbenicek; Frank Schneider; Hiltraud Hosser; Bogdan Ștefan Vasile; Ecaterina Andronescu; Frederik Wenz; Frank A Giordano; Carsten Herskind; Marlon R Veldwijk
Journal:  Int J Mol Sci       Date:  2021-06-24       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.